Title |
Uridine Prevents Fenofibrate-Induced Fatty Liver
|
---|---|
Published in |
PLOS ONE, January 2014
|
DOI | 10.1371/journal.pone.0087179 |
Pubmed ID | |
Authors |
Thuc T. Le, Yasuyo Urasaki, Giuseppe Pizzorno |
Abstract |
Uridine, a pyrimidine nucleoside, can modulate liver lipid metabolism although its specific acting targets have not been identified. Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined. At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxisomal bifunctional enzyme (ECHD) and acyl-CoA oxidase 1 (ACOX1), and induces excessive accumulation of long chain fatty acids (LCFA) and very long chain fatty acids (VLCFA). Uridine co-administration at a daily dosage of 400 mg/kg raises NAD(+)/NADH ratio, inhibits fenofibrate-induced hyper-acetylation of ECHD, ACOX1, and reduces accumulation of LCFA and VLCFA. Our data indicates a therapeutic potential for uridine co-administration to prevent fenofibrate-induced fatty liver. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 15 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 20% |
Student > Ph. D. Student | 3 | 20% |
Researcher | 2 | 13% |
Professor | 1 | 7% |
Student > Postgraduate | 1 | 7% |
Other | 0 | 0% |
Unknown | 5 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
Biochemistry, Genetics and Molecular Biology | 1 | 7% |
Business, Management and Accounting | 1 | 7% |
Nursing and Health Professions | 1 | 7% |
Computer Science | 1 | 7% |
Other | 2 | 13% |
Unknown | 7 | 47% |